RxDoctor Payments Data

Bufford Moore, MD

Family Medicine · Baytown, TXNPI 1881697183

Payments from drug & device makers

$4,528in general payments, 2019–2025

Across 161 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$747
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$641
  • Lilly USA, LLC$446
  • Astellas Pharma US Inc$218
  • GSK$211
  • Smith+Nephew$175
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,528 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$42,366
Medicare patients
131
Services billed
758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$31,294
FarxigaDapagliflozin Propanediol18$22,901
JardianceEmpagliflozin16$21,861
MounjaroTirzepatide15$20,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$20,251
EliquisApixaban13$19,196
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$12,001
Breo ElliptaFluticasone/Vilanterol18$10,296
Albuterol Sulfate HfaAlbuterol Sulfate83$2,140
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$2,097
Rosuvastatin Calcium92$1,652
Gabapentin72$1,468
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,384
Atorvastatin Calcium129$1,273
SynthroidLevothyroxine Sodium12$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$747$34,90335 claims
Novo NordiskOzempic$158$31,29426 claims
GSKTrelegy Ellipta, Breo Ellipta$211$30,54738 claims
Boehringer IngelheimJardiance$23$21,86116 claims
Lilly USA, LLCMounjaro$446$20,56215 claims
PfizerEliquis$130$19,19613 claims
AbbVieSynthroid$138$1,20212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Baytown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →